Values First Advisors Inc. Cuts Stock Position in argenx SE (NASDAQ:ARGX)

Values First Advisors Inc. cut its stake in shares of argenx SE (NASDAQ:ARGX) by 12.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,049 shares of the company’s stock after selling 145 shares during the period. Values First Advisors Inc.’s holdings in argenx were worth $645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisors Preferred LLC purchased a new position in argenx during the 4th quarter worth $73,000. Cromwell Holdings LLC increased its stake in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the period. GAMMA Investing LLC raised its holdings in argenx by 44.8% during the fourth quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock worth $155,000 after purchasing an additional 78 shares in the last quarter. Blue Trust Inc. lifted its position in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the period. Finally, Keudell Morrison Wealth Management purchased a new stake in argenx in the 3rd quarter valued at approximately $207,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Truist Financial reissued a “buy” rating and set a $700.00 target price (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Guggenheim boosted their target price on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. JMP Securities increased their price target on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Finally, Wells Fargo & Company boosted their price objective on shares of argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Stock Up 2.1 %

Shares of NASDAQ:ARGX opened at $649.09 on Thursday. The company has a market capitalization of $39.44 billion, a P/E ratio of -737.60 and a beta of 0.58. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21. The stock’s fifty day simple moving average is $638.76 and its 200-day simple moving average is $580.34.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.